NCT03258671 - IMRT and Timing in Combination With EGFRTKI for Stage IV Non-small-cell Lung Cancer | Biotech Hunter

Enrollment

160

Participants

Timeline

Start Date

October 1, 2017

Primary Completion Date

December 30, 2020

Study Completion Date

December 30, 2020

Conditions

Non-Small Cell Lung CancerNonsmall Cell Lung CancerCarcinoma, Non-Small-Cell Lung

Interventions

DRUG

EGFR-TK Inhibitor

·EGFR-TKI：gefitinib will be administered 250mg/d ivgtt qd; icotinib will be administered 150mg/d ivgtt tid;

RADIATION

Intensity Modulated Radiation Therapy

"High dose group：DTGTV=70Gy；~* first course radiotherapy：40Gy/20f/4w（DTPTV：36Gy/20f/4w）,2Gy/f/d；~* late course radiotherapy：1.5Gy/f、2f/d、interval≥6 hs、DTGTV=30Gy（DTPTV=27Gy）。~Low dose group：DTGTV=50Gy;~* first course radiotherapy：32Gy/16f/3w（DTPTV为28.8Gy/16f/3w），2Gy/f/d；~* late course radiotherapy：1.5Gy/f、2f/d、interval≥6小时、DTGTV为18Gy（DTPTV为16.2Gy）。"

Trial Locations (1)

550004

The affiliated hospital of Guizhou medical university, Guiyang